What if a drug known for treating parasites could also take on cancer cells? It sounds like a plot twist straight out of a sci-fi movie, but researchers are seriously investigating the potential of ivermectin in the cancer battleground. This humble antiparasitic has been showing some impressive preclinical antitumor effects. It can inhibit cancer cell proliferation, metastasis, and even stop the blood supply that tumors need to grow—talk about a multitasker.
In the lab, ivermectin has shown to mess with multiple signaling pathways. It targets PAK1 kinase, which is like a boss in the cancer world, regulating everything from cell survival to growth. It even promotes programmed cell death—apoptosis, autophagy, pyroptosis. That’s right, it’s throwing a party for cancer cells, and they’re not invited. Plus, it can even reverse multidrug resistance, which is a massive headache in cancer treatment.
Breast cancer, colorectal cancer, melanoma—the list goes on. Ivermectin appears to reduce proliferation in various cancer cell lines. In breast cancer, it shuts down the Akt/mTOR pathway, inducing autophagy, and it’s also been shown to block the Wnt/β-catenin pathway in colorectal cancer. Notably, in the context of TNBC, recent studies indicate that ivermectin can induce T-cell infiltration into tumors, which could enhance its anticancer effects.
Ivermectin is showing promise in battling breast and colorectal cancers by targeting key growth pathways and inducing cell death.
When it comes to downregulating PAK1, the results speak volumes. If you silence PAK1, bye-bye anticancer activity.
But hold your horses! Clinical evidence is still a mixed bag. Sure, preclinical studies show some promise, but large-scale randomized controlled trials? Not yet. A small trial with metastatic breast cancer didn’t exactly set the world on fire. Concerns from the medical community about the allocation of funding for this investigation remain unanswered.
And while some ongoing trials are taking a look at combining ivermectin with immunotherapy, the results remain uncertain. The National Cancer Institute is on the case, exploring ivermectin’s potential.
But let’s be real: translating these findings from the lab to humans is a whole different ball game. Until then, it’s a waiting game, folks.
